As of Feb 26
| +0.12 / +0.25%|
The 24 analysts offering 12-month price forecasts for GlaxoSmithKline have a median target of 46.38, with a high estimate of 52.25 and a low estimate of 38.10. The median estimate represents a -3.05% decrease from the last price of 47.84.
The current consensus among 27 polled investment analysts is to Hold stock in GlaxoSmithKline. This rating has held steady since February, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.